ShareThis Page
Pitt team gets $5.8M grant to develop liver device to enhance research |

Pitt team gets $5.8M grant to develop liver device to enhance research

| Wednesday, September 24, 2014 11:55 p.m

A device that mimics the human liver under development at the University of Pittsburgh could make it easier for researchers to test pharmaceuticals without animal trials, a leading medical scholar says.

A Pitt team led by D. Lansing Taylor won a $5.8 million, three-year grant from the National Institutes of Health to pursue the project, the university announced Wednesday. It’s part of a federal program at 11 institutions, all collaborating on a unified system that can replicate brain, kidney and other critical organ functions for research use.

If it works, Taylor said, the endeavor could give researchers more reliable tools to explore how diseases and drug therapies work before they try treatments on people.

Long-established animal testing of new drugs often fails to reveal effects that can be toxic to humans, missing that mark in about 30 to 50 percent of cases, he said.

“The joke is that we’ve been able to cure cancer — in a mouse. The human physiology is distinct,” said Taylor, the Allegheny Foundation professor of computational and systems biology at the Pitt School of Medicine.

He said the effort could set a foundation for better general therapies and tailored, personalized critical care, such as treatments based on a patient’s genetics.

Pitt scholars began the work two years ago and have developed a basic liver platform that fits in the palm of a hand. It’s not clear how researchers will size their refined final model, which Taylor said will be linked over the next few years with kidney, gut and brain models in the works at other institutions.

The initial liver device combines human cells, sensors and other man-made materials to let researchers monitor how a real liver should handle different kinds of medical care.

NIH Director Francis S. Collins praised such devices in a statement, calling their development a “remarkable marriage of biology and engineering.”

Taylor said more than a half-dozen people at Pitt are working on the project. He predicted drug testing based on the models could emerge within a decade.

“We’ve already had great success demonstrating early capabilities,” he said. “This is not going to change medicine in the next one or two years, but developments over this next decade will dramatically change the way drugs are tested and human diseases are studied.”

Adam Smeltz is a staff writer for Trib Total Media. He can be reached at 412-380-5676 or

Categories: Health Now
TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.